At a median follow-up of 7.2 years , failure to obtain a PSA-CR was associated significantly with worse disease-specific survival ( P = .0003 ; hazard ratio [ HR ] , 2.03 ; 95 % confidence interval [ CI ] , 1.38-2 .97 ) , with worse disease-free survival ( P = .003 ; HR , 1.28 ; 95 % CI , 1.09-1 .50 ) , and with a higher incidence of distant metastasis ( P = .0002 ; HR , 1.92 ; 95 % CI , 1.37-2 .69 ) and biochemical failure ( P < .0001 ; HR , 1.57 ; 95 % CI , 1.29-1 .91 ) .
